Schering and Merck Are Settling Vytorin Suits
Thursday, August 6, 2009 - 00:14
in Health & Medicine
Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.
Read the whole article on NY Times Health
More from NY Times Health
Related
- Obsidian 'trail' provides clues to how humans settled, interacted in Kuril IslandsMon, 22 Jun 2009, 13:42:24 EDT
- Vioxx trial data shows early cardiovascular riskMon, 23 Nov 2009, 17:18:01 EST
- When young men are scarce, they're more likely to play the field than to proposeTue, 9 Jun 2009, 19:49:24 EDT
- Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not knownTue, 28 Oct 2008, 16:43:02 EDT
- Small islands given short shrift in assembling archaeological recordThu, 30 Oct 2008, 14:36:32 EDT